secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001104659-24-089068
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents Q2 product sales up 10%, operating loss halved; DrugSorb-ATR submission on track
--------------------------------------------------------------------------------

- Total revenue $9.9M (+5% YoY); product sales $8.8M (+10%); gross margins improved to 75%.
- Operating loss narrowed 48% to $3.4M from $6.6M; additional cost cuts expected to save $5M annually.
- CFO Kathleen Bloch retired; Peter Mariani appointed as new CFO effective August 14, 2024.
- On track to submit DrugSorb-ATR marketing applications to U.S. FDA and Health Canada this quarter.
- Secured $20M credit facility with Avenue Capital; cash and restricted cash $14.9M as of June 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924089068/0001104659-24-089068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924089068/tm2421554d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer